title: [Ibandronate as a new therapeutic agent for osteoporosis].
abstract: Ibandronate, a second generation amino-bisphosphonate has a high potency as much as the third generation bisphosphonates. Therefore this compound can be characteristically administrated by means of bolus intravenous injection. Moreover it is the first bisphosphonate prospectively shown antifracture efficacy for the intermittent administration in a randomized, controlled clinical trial.
authors.affiliation: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Goto
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
mesh_terms: D000284:Administration, Oral; D017326:Clinical Trials, Phase III as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007275:Injections, Intravenous; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D004164:Diphosphonates; D000077557:Ibandronic Acid